Trials / Unknown
UnknownNCT04831541
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- First Affiliated Hospital of Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the potential usefulness of 68Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions, efficacy assessment and recurrence monitoring in various types of cancer.
Detailed description
Subjects with various types of cancer underwent 68Ga-PSMA-11 PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga-PSMA-11 PET/CT were calculated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-PSMA-11 | Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time. |
Timeline
- Start date
- 2020-10-10
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2021-04-05
- Last updated
- 2023-09-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04831541. Inclusion in this directory is not an endorsement.